Trio of drugs may fight "triple negative" cancer (science daily)

PharmaLive.com (December 10, 2010) - resistance to medicines, a cocktail of triple-drug for breast cancer gene target triple negative and the risk of carpal tunnel syndrome patients are among the points highlights study to be presented by researchers at the Johns Hopkins Kimmel Cancer Center at the 33rd Annual CTRC - AACR San Antonio Cancer Symposium, held from 8 to 12 December.

In collaboration with cell cultures and mice models, researchers at the Johns Hopkins Kimmel Cancer Center have tested a cocktail of three promising drugs for the treatment of what is known as triple negative cancer.

Women with these cancers are missing hormone receptor 3 - estrogen and progesterone and human epidermal growth factor 2 (HER2). Currently, the triple negative breast cancers treatments are limited to surgery, chemotherapy and radiotherapy, which provide some improvements, but overall prognosis.

In the new study, scientists at the Johns Hopkins University has begun with a drug called Entinostat, blocks the enzyme that happens to make regulatory genes in the DNA molecules and reactivates a gene called Retinoic acid receptor beta (RARß). Then they have added a drug called all Trans Retinoic acid (Alliance), linked to vitamin A, which binds to a protein made by the reactivated RARß gene. Overall, drug Alliance and gene RARß act as an impediment to the growth of cancer cells. Scientists completed the cocktail of drugs by conventional chemotherapy in low doses of doxorubicin or paclitaxel.

According to scientists, each of the three drugs used alone may have an effect on the Elimination of tumor cells but by combining tips the scale in favour of the Elimination of cells more.

Cells grown in laboratory tests have shown that triple therapy from the drop-down list box stopped the growth of multiple triple negative breast cancer cell lines more effectively as one of the only treatments. The combination therapy also rejuvenated RARß expression and strongly inhibited tumor growth in all three quarters mice grafted with breast tumor cells.

Researchers discuss potential clinical trials of the drop-down list box therapy hoping to start next year, says Nguyen k. Nguyen, a graduate student in cellular and molecular medicine at the Johns Hopkins University program.

Warning: this article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those PharmaLive.com or its staff.

Source of the story:

The story above is reproduced (with drafting adaptations by staff at PharmaLive.com) materials provided by Johns Hopkins Medical Institutions, via EurekAlert!, a service of AAAS.

Note: If no author is given, the source is cited for this.

Trio of drugs may fight "triple negative" cancer (science daily)

PharmaLive.com (December 10, 2010) - resistance to medicines, a cocktail of triple-drug for breast cancer gene target triple negative and the risk of carpal tunnel syndrome patients are among the points highlights study to be presented by researchers at the Johns Hopkins Kimmel Cancer Center at the 33rd Annual CTRC - AACR San Antonio Cancer Symposium, held from 8 to 12 December.

In collaboration with cell cultures and mice models, researchers at the Johns Hopkins Kimmel Cancer Center have tested a cocktail of three promising drugs for the treatment of what is known as triple negative cancer.

Women with these cancers are missing hormone receptor 3 - estrogen and progesterone and human epidermal growth factor 2 (HER2). Currently, the triple negative breast cancers treatments are limited to surgery, chemotherapy and radiotherapy, which provide some improvements, but overall prognosis.

In the new study, scientists at the Johns Hopkins University has begun with a drug called Entinostat, blocks the enzyme that happens to make regulatory genes in the DNA molecules and reactivates a gene called Retinoic acid receptor beta (RARß). Then they have added a drug called all Trans Retinoic acid (Alliance), linked to vitamin A, which binds to a protein made by the reactivated RARß gene. Overall, drug Alliance and gene RARß act as an impediment to the growth of cancer cells. Scientists completed the cocktail of drugs by conventional chemotherapy in low doses of doxorubicin or paclitaxel.

According to scientists, each of the three drugs used alone may have an effect on the Elimination of tumor cells but by combining tips the scale in favour of the Elimination of cells more.

Cells grown in laboratory tests have shown that triple therapy from the drop-down list box stopped the growth of multiple triple negative breast cancer cell lines more effectively as one of the only treatments. The combination therapy also rejuvenated RARß expression and strongly inhibited tumor growth in all three quarters mice grafted with breast tumor cells.

Researchers discuss potential clinical trials of the drop-down list box therapy hoping to start next year, says Nguyen k. Nguyen, a graduate student in cellular and molecular medicine at the Johns Hopkins University program.

Warning: this article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those PharmaLive.com or its staff.

Source of the story:

The story above is reproduced (with drafting adaptations by staff at PharmaLive.com) materials provided by Johns Hopkins Medical Institutions, via EurekAlert!, a service of AAAS.

Note: If no author is given, the source is cited for this.

Drugs can pass through the body virtually intact: new concerns for resistance to antibiotics, identified pollution (science daily)

PharmaLive.com (7 December 2010) - an antibiotic is consumed, the researchers learned that up to 90% through a body without metabolize. This means that drugs may leave almost intact body through normal bodily functions.

In the case of agricultural areas, antibiotics excreted excreted can then capture stream and River through various ways, including releases of animal feeding operations, hatcheries and diffuse sources such as the flow fields environments where manure or biosolids applied. Water filtered through wastewater treatment may also contain antibiotics used plants.

Therefore, these releases are "potential sources of genes for resistance to antibiotics," said Amy Pruden, a grant from National Science Foundation career and teacher assistant of civil and environmental engineering at Virginia Tech.

Pruden says "the presence of antibiotics even at sub-inhibitory concentrations can stimulate bacterial metabolism and thus contribute to the selection and maintenance of antibiotic resistance genes". "Once they are present in the rivers, the antibiotic resistance genes are capable of being transferred in bacteria, including pathogens by horizontal gene transfer".

The World Health Organization and the Center for Disease Control recognize antibiotic resistance '"as a major health challenge critical of our time", wrote in an article published in a number of science technology and environment 2010 Pruden.

Pruden says that reduce the spread of resistance to antibiotics is a critical measure necessary to prolong the efficacy of currently available antibiotics. This is important given that the "new drug discovery can no longer keep pace with new antibiotic-resistant infections", explains Pruden.

Pruden has developed the concept of genes for resistance to antibiotics as environmental pollutants enjoys an international reputation in applied microbial ecology, environmental remediation and environmental reservoir of antimicrobial resistance.

In his work described in the science and environmental technology article, she and her co-authors, h. Storteboom, M. Arabi and J.G. Davis, all of Colorado State University and (b) criminal Delft University, the Netherlands identified specific patterns of occurrence of resistance gene to antibiotics in a Colorado watershed. Identification of these schemas represents a milestone to be able to distinguish between agriculture and wastewater from these genes in river environments treatment plant sources.

They say that these unique patterns of occurrence of the antibiotic resistance gene represent promising molecular signatures which can then be used as tracers of some artificial sources.

In their study, they identified three sites of mill wastewater, location of six animal feeding operation and three other locations on a blank area of the powder River in upstream section located in the Rocky Mountains. The frequency of detection of resistance genes were compared antibiotic sulfonamides 11 and tetracycline.

Their findings showed the detection of a particular 100 percent of the processing plant antibiotic resistance gene and feeding operations, but only once in the clean section of animals Powder River.

They are able to distinguish between human and animal genes of resistance to antibiotics, Pruden and his colleagues believe that they can "shed light on areas where intervention may be more effective to help reduce the spread of these contaminants in environmental matrices such as soil, groundwater, surface water and sediments."

"This study advances the recognition of the genes for resistance to antibiotics as sources to affected communities, taking an important step in the identification of dominant processes spread and transport of the resistance genes to antibiotics."

Colorado water resources Research Institute and a USDA Agricultural Experiment Station funded study alongside NSF awards the Pruden.

Warning: this article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those PharmaLive.com or its staff.

Source of the story:

The story above is reproduced (with drafting adaptations by staff at PharmaLive.com) materials provided by Virginia Tech, via EurekAlert!, a service of AAAS.

Reference of the review:

Heather Storteboom, Mazdak Arabi, Jessica g. Davis, Barbara Crimi, Amy Pruden. Monitoring of the genes for resistance to antibiotics in the basin of the Platte River South to urban, agricultural, molecular signatures and pristine sources. Environmental Science & Technology, 2010; 44 (19): 7397 DOI: 10.1021/es101657s

Note: If no author is given, the source is cited for this.